The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
J-147's discovery story is as important as its pharmacology. It emerged from a deliberate methodological rebellion against the dominant paradigm of Alzheimer's drug development — and its unexpected molecular target later proved that rebellion correct.
By 2011, Alzheimer's drug development had spent two decades and tens of billions of dollars on the amyloid-beta hypothesis: the idea that removing amyloid plaques from the brain would halt or reverse Alzheimer's disease. Drug after drug targeting amyloid production, aggregation, or clearance had entered clinical trials and failed. The scientific debate about whether amyloid is a cause or consequence of Alzheimer's was unresolved, but the clinical trial failures were accumulating. David Schubert's Cellular Neurobiology Laboratory at the Salk Institute took a different approach. Rather than designing compounds to hit specific molecular targets — amyloid, tau, or any other known Alzheimer's protein — Schubert's group built a phenotypic screening platform that measured a compound's ability to reverse multiple cellular hallmarks of brain aging: oxidative stress, loss of neurotrophic factor signaling, mitochondrial dysfunction, and inflammatory stress. The logic: if you can find a compound that makes aging brain cells look and function more like young brain cells, you have found something relevant to Alzheimer's regardless of which molecular target it hits — because aging is Alzheimer's primary risk factor.
The screening program evaluated thousands of compounds from natural product libraries and synthetic derivatives. J-147 emerged as a potent hit: effective at nanomolar concentrations in the cell culture assays, with an in vitro safety profile (EC50/toxicity ratio over 750-fold) suggesting a substantial therapeutic window. Structurally, J-147 was derived from curcumin — specifically from a synthetic modification of a curcumin-related aromatic aldehyde condensed with a cyclohexyl amine to form the phenyl hydrazide scaffold. The resulting molecule shares some structural features with curcumin but is pharmacologically distinct: different molecular target, different pharmacokinetics, different bioavailability. What followed was 7 years of increasingly impressive mouse data without knowing what J-147 was actually doing at the molecular level.
THE CENTRAL TENSION
J-147's story has two layers of tension. The first is pharmacological: a compound discovered by phenotypic screening without knowing its target turned out to hit one of the most fundamental biological clocks in living organisms — ATP synthase, the enzyme that had already been shown to control aging in worms, flies, and was now being implicated in Alzheimer's through J-147. This is the discovery narrative that makes J-147 scientifically significant. The second tension is translational: the mouse data is among the most compelling in the longevity pharmacology literature — reversed brain aging biomarkers, prevented hippocampal transcriptome aging, extended Drosophila lifespan, reversed cognitive impairment in old Alzheimer's mice at an age equivalent to late human Alzheimer's. A Phase 1 human safety trial has been conducted. And yet no Phase 2 efficacy trial has been announced or initiated. The compound has been in development for over a decade with extraordinary preclinical data and no human efficacy evidence. Understanding why the clinical development has been slow is part of understanding J-147's position in the field.
J-147's AMPK/mTOR mechanism positions it within the same canonical longevity pathway that multiple other compounds in this book address — but via a unique upstream entry point. The comparison is instructive for understanding the mechanistic landscape of longevity pharmacology.
Compound
Mechanism
Entry Point
Human Evidence
J-147
ATP5A → Ca2+ → CAMKK2 → AMPK → mTOR inhibition
ATP synthase modulation
Phase 1 safety (NCT03838185); pending publication
Rapamycin
Direct mTORC1 inhibition
mTOR direct inhibitor
Grade A — approved immunosuppressant; longevity use repurposed; ITP mouse lifespan extension replicated
Metformin
Complex I inhibition → AMPK activation
Mitochondrial Complex I
Grade A — FDA-approved T2D drug; TAME human longevity trial ongoing
MOTS-c
Direct AMPK activation (AICAR pathway)
AMPK direct activator
Grade B — human RCT (Ryu 2023); WADA banned S4.4
ATX-304 (O-304)
AMPK activation
AMPK multi-agonist
Grade B — Phase 2b human data; WADA banned S4.4
5-Amino-1MQ
NNMT inhibition → NAD+ preservation → SIRT1 → AMPK
Upstream of NAD+/SIRT1
Grade D — mouse IP data only; no human trials
J-147's ATP synthase → CAMKK2 → AMPK pathway is the most upstream and least understood entry point into the AMPK longevity pathway of any compound in the table. This is both its scientific novelty and its clinical uncertainty — the AMPK activation produced by this novel route may have quantitatively and qualitatively different downstream effects from direct AMPK activation (MOTS-c, ATX-304) or Complex I inhibition (metformin). Whether these distinctions produce clinically meaningful differences will require head-to-head human data.
J-147's mechanism, once discovered in 2018, revealed an unexpected molecular link between aging and dementia — and connected J-147 to the same longevity pathway activated by rapamycin, MOTS-c, and ATX-304 through a completely novel upstream entry point.
ATP synthase (Complex V, F0F1-ATPase) is the enzyme responsible for the final step of oxidative phosphorylation: using the proton gradient across the inner mitochondrial membrane to drive synthesis of ATP from ADP and inorganic phosphate. It consists of two major components: F0 (embedded in the IMM, the proton channel) and F1 (the catalytic head, projecting into the mitochondrial matrix). The F1 component is further composed of multiple subunits including the alpha subunit (ATP5A). J-147 binds the ATP5A subunit — identified via thermal proteome profiling (a technique that identifies binding partners by measuring changes in protein thermal stability upon compound binding) and confirmed by photoaffinity labeling and co-immunoprecipitation. The binding modulates ATP synthase's catalytic activity in a way that changes the cellular energy sensing state without fully inhibiting ATP production.
J-147's binding to ATP5A produces the following downstream cascade: (1) Modified ATP synthase activity alters the coupling efficiency of the proton gradient to ATP synthesis; (2) This triggers increased intracellular calcium (Ca2+) — the mechanism is not simply reduced ATP synthesis but a specific coupling change that modifies Ca2+ handling; (3) Elevated intracellular Ca2+ activates CAMKK2 (calcium/calmodulin-dependent protein kinase kinase beta) — a kinase that responds to Ca2+ signals; (4) CAMKK2 phosphorylates and activates AMPK (AMP-activated protein kinase); (5) AMPK inhibits mTORC1 and activates FOXO transcription factors — producing the canonical longevity transcriptional response; (6) Downstream: BDNF upregulation; mitochondrial biogenesis; suppression of inflammatory pathways (NF-κB); neuroprotection against multiple age-related toxicities. This is the same AMPK/mTOR longevity axis activated by rapamycin (via mTORC1 direct inhibition), MOTS-c (via AMPK activation), and metformin (via Complex I inhibition/AMPK) — but via an entirely novel upstream entry point through ATP synthase modulation and Ca2+-dependent CAMKK2.
One of the most compelling validations of J-147's mechanism is evolutionary: ATP synthase has been independently shown to control aging in multiple model organisms before J-147 was developed. In C. elegans (nematode worms), RNAi knockdown of ATP synthase subunits extends lifespan. In Drosophila, ATP synthase subunit modulation affects aging rates. The Goldberg 2018 paper in Aging Cell confirmed that J-147 itself extends lifespan in Drosophila — not just in mice. This cross-species conservation means that the ATP synthase-aging connection is not a mouse-specific artifact but a fundamental feature of mitochondrial energy metabolism and its role in cellular aging across phyla. It also provides a strong argument that the mechanism is relevant to human aging — though human clinical validation remains the necessary next step.
Beyond the longevity/aging pathway, J-147 produces significant BDNF (brain-derived neurotrophic factor) upregulation in cell culture at nanomolar concentrations. BDNF is the primary neurotrophic factor supporting neuronal survival, synaptic plasticity, hippocampal neurogenesis, and learning and memory consolidation. BDNF levels decline with aging and are reduced in Alzheimer's disease — restoration of BDNF is one of the proposed mechanisms of action for exercise, antidepressants, and multiple other cognitive interventions. J-147's BDNF induction provides the mechanistic basis for its cognitive enhancement and neuroprotective effects beyond the AMPK/aging pathway. For the community using J-147 as a nootropic: the BDNF mechanism is the most directly relevant to the cognitive enhancement experience reported, as BDNF acutely supports synaptic plasticity and learning processes in the hippocampus and prefrontal cortex.
J-147 has one of the richest preclinical evidence bases of any compound in this book. It also has one key gap: Phase 2 efficacy data in humans.
Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. (2013). The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimer's Research & Therapy. 5(3):25. PMC3706879. This is J-147's defining efficacy paper. Design: 20-month-old APPswe/PS1ΔE9 double-transgenic mice — one of the most established familial AD mouse models; at 20 months these mice have significant amyloid pathology and cognitive impairment; fed J147 (200 ppm, approximately 10 mg/kg/day) for 2 weeks. Results: statistically significant improvement in Y-maze spontaneous alternation (working memory); Morris water maze probe trial performance; contextual and cued fear conditioning — all three independent behavioral measures of memory improved vs untreated old AD mice. The key design feature: treating 20-month-old mice (equivalent to very elderly humans with established AD) rather than preventing pathology in young mice — the reverse of most AD mouse studies. Grade C: established AD mouse model; Salk Institute group; single institution; but strong behavioral battery and treatment of established disease rather than prevention.
Currais A, Prior M, Fischer W, et al. (2019). Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function and impedes glial activation in old mice. Aging Cell. (Note: the J-147 brain aging reversal data also published in multiple Currais/Schubert papers in this period.) The SAMP8 study: SAMP8 mice (senescence-accelerated mouse-prone 8) are a model of sporadic Alzheimer's-like aging — they age rapidly and develop cognitive impairment similar to human age-related cognitive decline rather than familial AD. J-147-treated SAMP8 mice showed comprehensive reversal of aging biomarkers: hippocampal gene expression profiles resembling young mice; plasma metabolome profiles resembling young mice; over 500 small molecules in brain and blood analyzed. The framing from the Salk Institute: 'old mice on J-147 looked like young mice.' This is the data that the popular science headline 'drug reverses aging in mice' was based on.
Goldberg J, Currais A, Prior M, et al. (2018). The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 17(3):e12715. PMC5847861. doi:10.1111/acel.12715. This is the most scientifically significant J-147 publication — the one that connected a specific molecular target to both Alzheimer's and aging simultaneously. Methods: thermal proteome profiling in SH-SY5Y cells (human neuroblastoma); photoaffinity labeling; co-immunoprecipitation; ATP synthase functional assays; Drosophila lifespan. Results: ATP5A identified as the binding target; AMPK/mTOR/CAMKK2 cascade confirmed; Drosophila lifespan extended; hippocampal transcriptome drift prevented in SAMP8 mice. Grade A (mechanism) — multiple independent techniques confirming the same target; evolutionary conservation validated in a second species; mechanistic clarity.
NCT03838185 (Abrexa Pharmaceuticals): randomized, double-blind, placebo-controlled, parallel-design; single ascending dose (SAD) in healthy young and elderly subjects; primary endpoints: safety/tolerability and pharmacokinetics. The trial was designed to answer the most basic human questions: is J-147 safe in humans, and what are its PK properties (bioavailability, half-life, plasma levels)? It was NOT designed to test cognitive efficacy. The trial was listed as completed in 2022-2023, but as of mid-2026, full peer-reviewed results have not been published in the accessible scientific literature. The community interprets this as either: the results confirmed safety (allowing further development) or the results showed unexpected issues (halting development). Without the published data, this remains uncertain. The CeeTox in vitro safety analysis (Lapchak 2013) showed a therapeutic safety window of 782-3600 fold between EC50 and CTox — reassuring preclinical safety data that supported the Phase 1 decision.
Study
Type
Grade
Key Finding
Prior 2013 (Alzheimer's Res Ther; PMC3706879)
Established AD transgenic mouse; behavioral battery
C
Reversed cognitive impairment in 20-month-old AD mice; Y-maze, water maze, fear conditioning; treatment of established disease not prevention
Currais/Goldberg series (2018-2019 Aging Cell)
SAMP8 rapidly-aging mice; transcriptome; metabolome
C
Brain aging reversed: hippocampal transcriptome + plasma metabolome of old mice resembled young mice; 500+ biomarkers analyzed
Goldberg 2018 (Aging Cell; PMC5847861)
Target ID: thermal proteome profiling; Drosophila lifespan
A (mechanism)
ATP5A identified as target; AMPK/mTOR/CAMKK2 cascade; Drosophila lifespan extended; evolutionary aging link confirmed
Lapchak 2013 (CeeTox safety)
In vitro toxicology
D (safety assay)
EC50/CTox ratio 782-3600 fold; not genotoxic; substantial therapeutic safety window supports Phase 1
Phase 1 NCT03838185
Human SAD safety + PK trial
B pending
Safety and PK in healthy young and elderly; trial appears completed ~2022; peer-reviewed publication not yet available mid-2026
Phase 2 efficacy
Human efficacy (AD or cognitive aging)
No grade — does not exist
No Phase 2 trial announced or initiated as of mid-2026
The most important C3 distinction for community users: J-147 is structurally inspired by curcumin but is pharmacologically, mechanistically, and pharmacokinetically distinct. Taking curcumin is not an approximation of taking J-147.
Feature
J-147
Curcumin
Molecular origin
Synthetic phenyl hydrazide derived from curcumin-related aldehyde + cyclohexyl amine condensation
Natural polyphenol from Curcuma longa (turmeric)
Molecular weight
~408 Da
~368 Da
Primary target
ATP synthase alpha-F1 subunit (ATP5A)
Multiple: NF-κB, COX-2, Nrf2, HDAC, others — not ATP synthase
Neuroprotection mechanism
ATP5A → Ca2+ → CAMKK2 → AMPK → BDNF
Anti-inflammatory (NF-κB), antioxidant (Nrf2), BDNF (indirect)
Oral bioavailability
Substantially higher than curcumin (by design)
Very poor — <1% oral bioavailability; rapidly metabolized
Blood-brain barrier penetration
Designed for CNS; J-147 crosses BBB
Very limited — one reason curcumin shows poor efficacy in AD trials
Alzheimer's mouse efficacy
Yes — multiple robust studies
Yes in some models, not others; effects inconsistent across studies
Human Alzheimer's trials
Phase 1 safety only; no Phase 2
Multiple Phase 2/3 trials run; none showed significant benefit
Community dosing
25-50 mg/day
500-8,000 mg/day (much higher due to poor bioavailability)
The key practical point: curcumin supplementation at any dose is not equivalent to J-147 because the molecular targets and mechanisms are different. Curcumin's failure in human Alzheimer's trials is not evidence that J-147 will fail — they are different compounds. J-147 was specifically engineered to overcome curcumin's poor bioavailability and CNS penetration. The community sometimes uses curcumin as a substitute or comparison compound for J-147 — this is a category error.
Community protocols for J-147 use 25-50 mg/day oral in most reported protocols, with some users going as high as 100 mg. The mouse studies used 200 ppm in food (approximately 10 mg/kg/day in mice), which translates to approximately 100 mg/day in a 70 kg human by simple allometric scaling — but oral bioavailability differences between mice and humans are unknown and may substantially change the effective human dose. The CeeTox safety analysis established a CTox of 90 μM in rat hepatoma cells, providing a broad safety window. No human dose-response data is available from the Phase 1 trial since results are not yet published.
Parameter
Community Standard
Notes
Form
Oral; capsule or powder
Good oral bioavailability by design; no special formulation needed
Starting dose
25 mg/day
Start conservatively; assess tolerability
Target dose
25-50 mg/day
Community-established range; some users use 100 mg/day
Frequency
Once daily
Morning preferred; no strong circadian rationale but cognitive effects consistent with morning use
With food
Yes — fat-containing meal
Lipophilic compound; fat improves absorption
Cycling
8 weeks on / 4 weeks off
Community convention; no pharmacological basis; AMPK tolerance unknown
Stacking
Rapamycin, NMN/NR, MOTS-c, ATX-304 for comprehensive AMPK/mTOR longevity stack
Mechanistically complementary; different entry points into the same longevity pathway; no published interactions
WHAT COMMUNITY USERS REPORT
J-147 is described in community reports as producing a subtle but consistent cognitive enhancement: clearer thinking, improved recall during demanding cognitive tasks, easier verbal fluency, and mild mood lift. The effects are described as 'clean' — no stimulatory or sedating quality, no crash. Onset is gradual — most users report nothing in the first week, with effects accumulating over 2-4 weeks. This timeline is consistent with a BDNF-mediated mechanism (BDNF upregulation produces structural synaptic changes that take weeks to manifest as measurable cognitive improvement). Some users report decreased brain fog and improved emotional regulation, consistent with the neuroinflammatory reduction mechanism. These are community reports — no controlled cognitive testing has been done in the human nootropic context.
J-147 and curcumin share structural inspiration but are pharmacologically distinct compounds. Curcumin's primary targets include NF-κB, COX-2, Nrf2, and HDAC — not ATP synthase. Curcumin has <1% oral bioavailability and does not reliably cross the blood-brain barrier. J-147 was specifically engineered to improve on curcumin's pharmacological limitations. Multiple human clinical trials of curcumin for Alzheimer's disease failed to show benefit. This is not evidence that J-147 will fail — it is evidence that curcumin's mechanism and pharmacokinetics do not produce efficacy in humans for this indication. J-147 has different properties. Turmeric is not a reasonable substitute.
Mouse brain aging reversal data — even with comprehensive transcriptome and metabolome analysis — is not proof of human efficacy. The J-147 mouse data is among the most compelling preclinical longevity data in this entire book. It also cannot substitute for human clinical trials. Multiple compounds have shown dramatic age-reversal effects in mice and failed in humans (rapamycin, metformin, and others were in this situation before eventually accumulating human evidence). J-147 is at the stage where the mouse data justifies Phase 2 human trials — those trials have not yet been conducted.
The Phase 1 trial (NCT03838185) appears to have been completed but peer-reviewed results have not been published as of mid-2026. A Phase 1 SAD (single ascending dose) study in healthy volunteers tests safety and pharmacokinetics — it does not test chronic safety (weeks or months of dosing), efficacy, or safety in the elderly Alzheimer's population. If the Phase 1 showed the compound was safe and had reasonable pharmacokinetics, the appropriate next step would be Phase 2 efficacy trials. The community use of J-147 at 25-50 mg/day chronically extends beyond what Phase 1 SAD study safety data covers.
Both activate the AMPK/mTOR longevity pathway, but through entirely different mechanisms that converge downstream. Rapamycin directly inhibits mTORC1. J-147 activates AMPK upstream of mTOR via ATP synthase → Ca2+ → CAMKK2. The downstream effects partially overlap (mTOR inhibition, autophagy promotion) but the upstream pharmacology, off-target profiles, and magnitude of effects differ substantially. Rapamycin has Grade A longevity evidence in multiple species and human pharmacokinetic data from decades of clinical use. J-147 has Grade C-B evidence with Phase 1 safety data. They should not be treated as interchangeable.
Goldberg J, Currais A, Prior M, et al. (2018). The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 17(3):e12715. PMC5847861. doi:10.1111/acel.12715. [Target identification: ATP5A via thermal proteome profiling; CAMKK2/AMPK/mTOR cascade; Drosophila lifespan extension; hippocampal transcriptome drift prevention; the key 2018 paper that connected J-147's mechanism to canonical aging biology.]
Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. (2013). The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimer's Research & Therapy. 5(3):25. PMC3706879. doi:10.1186/alzrt179. [20-month-old APPswe/PS1ΔE9 AD mice; J147 reversed cognitive impairment in established disease; Y-maze, water maze, fear conditioning; treatment rather than prevention design; foundational efficacy paper.]
Currais A, Goldberg J, Farrokhi C, et al. Salk Institute series in Aging Cell (2019). SAMP8 rapidly-aging mice; J-147 prevents age-associated drift of hippocampal transcriptome and plasma metabolome; treated old mice resemble young mice across 500+ biomarkers. [The 'reversed brain aging' data in the sporadic AD model.]
Lapchak PA, Bombien R, Rajput PS. (2013). J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox Safety and Genotoxicity Analysis. Journal of Neurology & Neurophysiology. 4(4). PMC4215638. [In vitro safety analysis; CTox 90 μM; EC50/toxicity ratio 782-3600 fold; not genotoxic; establishes broad preclinical therapeutic safety window.]
NCT03838185 (Abrexa Pharmaceuticals). A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and PK of J147 in Healthy Subjects. Single ascending dose; healthy young and elderly subjects. [Phase 1 SAD safety and PK; trial completion reported ~2022; peer-reviewed publication pending as of mid-2026.]
J-147 is the compound in this book with the greatest gap between preclinical evidence quality and clinical translation velocity. The mouse data is extraordinary. The human development has been slow. The ATP synthase discovery changed how we think about the aging-dementia link.
The honest summary: J-147's discovery of ATP synthase as a molecular link between aging and Alzheimer's disease is one of the most interesting mechanistic findings in longevity pharmacology of the past decade. The compound activates the canonical AMPK/mTOR longevity pathway through an unprecedented upstream entry point — different from every other compound targeting this pathway. The mouse data is among the most compelling in the book: reversal of established cognitive impairment in 20-month-old AD mice; prevention of age-associated transcriptome drift in the SAMP8 model; Drosophila lifespan extension. A Phase 1 human safety trial has been conducted. And then — silence. No Phase 2, no peer-reviewed Phase 1 results, no announced development timeline. The community has filled this gap with research chemical use at 25-50 mg/day, reporting consistent subtle cognitive enhancement consistent with the BDNF/AMPK mechanism. For the longevity community, J-147 is the compound to watch — if Phase 2 is ever announced, it will be the most scientifically validated test of the AMPK longevity pathway in a human neurological context.
— End of J-147 —
THE PEPTIDE BIBLE | J-147 | For Research & Educational Purposes Only
J-147: synthetic phenyl hydrazide small molecule; MW ~408 Da; oral. Structurally derived from curcumin + cyclohexyl amine condensation. NOT curcumin — different target, mechanism, bioavailability, pharmacology. Developed by David Schubert group, Salk Institute, 2011. Commercialized by Abrexa Pharmaceuticals. DISCOVERY: phenotypic screen for compounds reversing cellular hallmarks of brain aging — not rational design. TARGET (identified 2018): mitochondrial alpha-F1-ATP synthase (ATP5A) — Goldberg et al. 2018, Aging Cell, PMC5847861. For 7 years after discovery, molecular target was unknown. MECHANISM: ATP5A binding → increased intracellular Ca2+ → CAMKK2 activation → AMPK activation → mTOR modulation → BDNF upregulation + mitochondrial stabilization + neuroprotection + neuroinflammation suppression. Same canonical AMPK/mTOR longevity pathway as rapamycin, metformin, MOTS-c — but via novel upstream entry through ATP synthase. EVOLUTIONARY VALIDATION: ATP synthase controls aging in C. elegans and Drosophila; J-147 extends Drosophila lifespan; confirms cross-species aging relevance. KEY PRECLINICAL: Prior 2013 (Alzheimer's Res Ther, PMC3706879): reversed cognitive impairment in 20-month-old APPswe/PS1ΔE9 AD mice; Y-maze, water maze, fear conditioning — all improved vs untreated old mice; Grade C. Currais/Goldberg series 2018-2019 (Aging Cell): SAMP8 rapidly-aging mice; hippocampal transcriptome + plasma metabolome of old J-147 mice resembled young mice; 500+ biomarkers; Grade C. SAFETY: Lapchak 2013 CeeTox analysis; CTox 90 μM; EC50/toxicity ratio 782-3600 fold; not genotoxic; Grade D. HUMAN: Phase 1 NCT03838185 (Abrexa Pharmaceuticals); DBRPC; SAD; healthy young and elderly; safety + PK; completed ~2022; peer-reviewed publication pending mid-2026. No Phase 2. COMMUNITY: 25-50 mg/day oral; fatty meal; morning; 2-4 weeks for effect; 8-week cycles; BDNF mechanism primary for nootropic application. J-147 vs CURCUMIN: different target (ATP5A vs NF-kB/COX-2); different bioavailability; curcumin failed human AD trials; J-147 has not run Phase 2 in humans; not substitutable. AMPK LANDSCAPE: different upstream entry from rapamycin (direct mTORC1), metformin (Complex I), MOTS-c (direct AMPK) — complementary not redundant. WADA: not listed. No HPTA. No active malignancy concern. No cancer concern.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.